653 results on '"Jewett, Michael A.S."'
Search Results
2. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis
3. Evidence-based Urology: Trustworthy Guidelines
4. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer
5. Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach
6. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor
7. Prognostic urinary miRNAs for the assessment of small renal masses
8. Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass
9. Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours
10. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma
11. Role of Active Surveillance for Localized Small Renal Masses
12. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor
13. Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance
14. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions
15. Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis
16. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions: Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board
17. The role of biopsy for small renal masses
18. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer
19. 2022 Global patient survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas.
20. A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis).
21. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy
22. Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology
23. The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPA
24. Treatment of localized renal cell cancer
25. Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma
26. Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly
27. The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy
28. Updated testicular cancer consensus guideline is a concise, balanced, and practical guide for clinicians
29. MicroRNAs in Kidney Disease: An Emerging Understanding
30. Outcomes after Radical Nephrectomy for Renal Cell Carcinoma
31. A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin
32. Results of a Surgically Derived Nomogram to Predict Gleason Score Upgrading Applied to a Cohort of Patients With “Favorable-risk” Prostate Cancer Treated With Permanent Seed Brachytherapy
33. Structured electronic operative reporting: Comparison with dictation in kidney cancer surgery
34. The FGFR3 Mutation is Related to Favorable pT1 Bladder Cancer
35. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients
36. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
37. Patient-centered care can be improved by joint meetings between cancer patient group leaders and health care providers
38. Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.
39. The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation
40. Salvage Therapy: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009
41. Most Renal Oncocytomas Appear to Grow: Observations of Tumor Kinetics With Active Surveillance
42. PHOTODYNAMIC THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER MEDIATED BY INSTILLED PHOTOSENSITIZER TLD1433 AND GREEN LIGHT ACTIVATION: MP61-06
43. Active Surveillance for Renal Neoplasms with Oncocytic Features is Safe
44. The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred
45. BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer
46. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma
47. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors
48. MP67-16 DETERMINING THE BEST COMPLETE BLOOD COUNT-BASED BIOMARKER FOR ONCOLOGIC OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER
49. MP50-13 CAN ONCOCYTOMAS BE SAFELY MONITORED BY SURVEILLANCE?
50. MP10-10 OUTCOMES OF PROGRESSION ON SURVEILLANCE FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOURS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.